Alpha Tau Medical

16/03/2026

to Present at March Virtual Small Cap Conference

Our CFO, Mr. Raphi Levy, will be available for 1x1 investor meetings at the conference.

Please reach out to your Sidoti representative to schedule.

Jerusalem, March 16, 2026 - Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference taking place on March 18 - 19, 2026.Mr. Levy...

09/03/2026

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment.

Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART skin cancer trial, in the U.S. pilot IMPACT pancreatic cancer trial, and in the U.S. recurrent glioblastoma multiforme feasibility trial.

$76.9 million in cash, cash equivalents & deposits provides continued balance sheet strength for clinical advancement and commercial preparation.

Read the full PR below:

https://www.alphatau.com/single-post/alpha-tau-announces-full-year-2025-financial-results-and-provides-corporate-update

24/02/2026

Alpha Tau Medical Receives Japanese Marketing Approval for ® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

https://lnkd.in/dNhemP6c

05/02/2026

Today at Alpha Tau Medical, we took some time to come together to mark one year since the passing of the late Professor Itzhak Kelson, a brilliant scientist whose vision helped bring the Alpha Dart® technology to life.

Since his passing, his influence has not faded; it has only grown stronger in the work we do every day. Itzhak’s scientific legacy continues to guide our innovation, but it is his character - warm, humble, endlessly curious, and full of gentle humor - that remains closest to our hearts and that is most deeply cherished.

Shai Lax, materials engineer, relayed some beautiful Jewish teachings, connecting them to Itzhak, to honor and elevate the moment.

Yadin Cohen, Head of Physics, spoke movingly about his relationship with Itzhak - about mentorship, collaboration, and the quiet brilliance that defined him. His words reminded us that Itzhak’s greatest impact was not only in the technologies he helped create, but in the people he encouraged, supported, and believed in.

Niv Golan played a lovely piece of music by Arik Einstein, a small but meaningful gesture that evoked Itzhak’s characteristic warmth and personality and love of culture.

Professor Kelson was more than a scientist. He was a kind friend and devoted mentor, a colleague whose presence made every conversation brighter and lighter. His contributions to science and physics are lasting and profound, but his legacy at Alpha Tau is equally defined by empathy, integrity, joy, and humor.

Today, we remember him with gratitude. As we continue to work hard to carry forward the legacy of his important work to bring hope to cancer patients around the world, we pause and reflect on where we came from, how far we’ve come, and how inspired we are to keep moving.

04/02/2026

On , we stand with patients and their families as we continue to pursue our mission to advance worldwide and to offer hope for those who need it most.

02/02/2026

New Horizons for Recurrent Skin Cancer Treatment
As featured in : "Less Invasive Skin Cancer Treatments"

Finding the right treatment for recurrent cutaneous squamous cell carcinoma ( ) can be a challenging journey, especially when traditional surgical options may not be the ideal path for every patient. For many patients, the challenge is finding a treatment that delivers clinical effectiveness while preserving quality of life, particularly in sensitive or previously treated areas.

Alpha Tau Medical is proud to spotlight the work of Dr. Jacob Beer, who is leading a pivotal clinical trial featuring our innovative ® technology. This approach uses highly localized, designed to target tumors from within while potentially minimizing impact on surrounding healthy tissue.

Through the clinical trial, we are working to expand access to new treatment pathways for patients with recurrent cSCC who may have limited options. At the same time, we aim to equip clinicians with an additional, precision-focused tool to address complex cases and advance patient-centered cancer care.

Alpha DaRT treatment for recurrent cSCC is currently available only as part of a clinical trial in the US.

For more information, please contact info@alphatau.com

Not to be the cloud in our sunny Florida sky, but it’s well known that our state has some of the highest rates of skin cancer in the country. Our year-round sunshine and strong ultraviolet (UV) exposure put residents at elevated risk. But skin cancer, particularly recurrent skin cancer, isn’t ju...

29/01/2026

Alpha Tau Medical Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal trial as well as trials in cancers of internal organs including the pancreas and brain -

- Ramping U.S. manufacturing for commercial readiness -

To see the full letter, please read:

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

20/01/2026

Alpha Tau Medical at 2026 - Advancing Combination Therapy in Head and Neck Cancer

Following the release of promising interim clinical trial data studying the Alpha DART® in combination with pembrolizumab as a treatment for locally advanced and metastatic , Alpha Tau continues to see strong interest in this clinical program. Prof. Aron Popovtzer, MD, Chair of the Sharett Institute of Oncology at Hadassah Medical Center and lead investigator of the study, will be attending the Multidisciplinary Head and Neck Cancers Symposium (MHNCS), February 19–21, 2026, in Palm Desert, California.

Prof. Popovtzer will be available to share insights and discuss potential collaboration opportunities related to the Alpha DART and pembrolizumab combination approach. We welcome meetings with colleagues interested in learning more. Please direct message us or email info@alphatau.com to connect.

19/01/2026

The United States is observing Rev. Dr. Martin Luther King Jr. Day, but the principles which are commemorated on this day extend far abroad as well. His legacy emphasized human dignity as central to progress. In medicine, these ideas are reflected in a growing focus on treating patients as individuals rather than simply as cases.

Alpha Tau Medical believes deeply in these principles and holds itself to these same high standards. While we are an Israeli company, the values associated with Dr. King’s legacy resonate worldwide. Our work is guided by a patient-centered approach, focusing on providing the patient with a tailored and minimally-invasive treatment which seeks to maximize quality of life and to respect for human dignity. May Dr. King's legacy be blessed to continue to resonate far and wide.

16/01/2026

J.P. Morgan week is always intense, and this year was no exception. From Sunday on, our CEO U*i Sofer and CFO Raphi Levy were in constant motion, meeting with investors from early morning through late night, making the most of a critical opportunity to share AlphaTau’s story and listen closely to the market.

The week culminated with Raphi taking the stage to present Alpha Tau Medical, delivering a clear message that felt like a fresh start rather than the end of a demanding week.

The high-energy engagement and strong feedback throughout the conference reinforced what we see every day: Alpha Tau is gaining momentum, our differentiated technology and value proposition are resonating well.

14/01/2026

Why a leading dermatology publication has its eyes on the AlphaDaRT®

The last few weeks have been a whirlwind of data and dialogue at ASCO GI and the J.P. Morgan Healthcare Conference. But amid all the conference buzz, a major step towards potential patient access is drawing particular attention in the field of skin cancer.

Dermatology Times recently highlighted Alpha Tau Medical submission to the FDA of the first module of a Pre-Market Approval (PMA) application for the Alpha DaRT as a treatment for recurrent cutaneous squamous cell carcinoma (cSCC), a condition for which treatment options are often exhausted.

As the article cites Dr. Robert Den, MD, our CMO: Alpha DaRT’s “ability to deliver potent, localized alpha radiation directly into the tumor bed allows us to be more aggressive against the cancer than ever before, while remaining conservative with the surrounding healthy skin.”

For skin cancer patients facing “untreatable” cases, Alpha DaRT may provide great benefit. The journey from clinical trial to patient bedside is moving fast.*

*Alpha DART is currently available only in the context of authorized clinical trials.

Check out the full article:
https://lnkd.in/dirjJk3b

13/01/2026

A year has passed… and somehow our CFO and CEO still haven’t mastered ping pong. 🏓

But what they have mastered is building amazing connections and relationships.

From to , we’ve made tremendous progress - advancing our intratumoral radiotherapeutic platform, deepening our clinical and commercial readiness, and positioning Alpha Tau Medical with high potential to lead in a fast-growing market with enormous patient impact.

We arrive at JPMorgan 2026 excited, motivated, and eager to share the many opportunities ahead.

The ping pong skills may still be a work in progress - but the momentum at Alpha Tau is very real.